

Small, Smart, Stealth Nanoparticles Seek-and-Destroy Metastatic Cancers, as Epeius Biotechnologies Advances its Intellectual Property Estate with Additional U.S. Patents

Tumor-targeted Gene Delivery Gains in Medicine and Patent Protection.

SAN MARINO, Calif., July 6 (SEND2PRESS NEWSWIRE) – Epeius Biotechnologies Corporation, an emerging leader in the field of [targeted genetic medicine](#), received a notice of allowance from the USPTO for another crucial patent covering its leading tumor-targeted gene delivery platform. The issuance of this high-value patent protection for targeting metastatic disease follows on the heels of two major patent issuances covering tumor-targeted gene delivery and precision-targeted cancer immunotherapy, respectively. Like the exceedingly tiny, precision targeted, stealthy tumor-seeking nanomedicine itself, this small California biotechnology company has advanced to the forefront of the biopharmaceutical “War on Cancer” with formal demonstrations of safety and efficacy in the clinic and best-of-breed solutions for the pharmaceutical industry.

As the development of its lead oncology product advances in the clinic towards regulatory approval, the critical proofs-of-principle, i.e., definitive demonstrations of overall safety and single-agent efficacy in clinical trials, serve as the scientific and innovative basis for attaining additional patent protections in the emerging field of tumor-targeted biologics. Indeed, Epeius Biotechnologies has accumulated more than 150 issued/allowed/granted patents in the area of genetic medicine, including more than 40 pending applications.

Furthermore, the U.S. FDA has recently granted Orphan Drug status to Rexin-G, the company’s lead product, for three separate clinical indications based on formal evaluations of clinical safety and potential efficacy, which provides additional market protections and economic incentives pertaining to such a significant and yet unmet medical need as the treatment of chemotherapy-resistant cancers.

Exhibiting broad-spectrum anti-cancer activity against many otherwise intractable cancers, Rexin-G has demonstrated a number of first-in-class, best-in-class characteristics: (1) The tumor-targeting properties of the gene delivery platform are profound, capable of seeking-out, accumulating-in, and halting-the-progression-of widespread cancers by means of simple intravenous infusions. (2) The broad-spectrum anti-cancer activity is achieved “by design,” as the genetic payload is focused on a critical locus of cellular growth control and tumor suppression. (3) Years of progressive clinical

trials have advanced the field by establishing cumulative safety (with no dose-limiting toxicities), practical pharmacological thresholds, quantitative dose-response relationships, and clinical infusion protocols which optimize patient benefits, including significant survival benefits. (4) Equally important are the advancements in biopharmaceutical science that provide for greater purities, potencies, GMP productivity, and economies-of-scale, and which translate into more-affordable treatments for cancer patients.

All in all, it seems that Small, Smart, and Stealth may turn out to be a very cool hand to grasp, and to hold on to.

About Epeius Biotechnologies:

Epeius Biotechnologies Corporation is a privately held biopharmaceutical company dedicated to the advancement of genetic medicine with the development and commercialization of its leading oncology products and its tumor-targeted delivery systems. Rixin-G® is currently approved for the treatment of all chemotherapy-resistant solid tumors by the Philippine FDA. To learn more about our lead products and/or our pipeline of proprietary biotechnologies, please visit us at www.epeiusbiotech.com.

For recent papers, expert reviews, clinical reports in oncology and molecular therapy, etc., see the "Publications" section on our website.

News issued by: Epeius Biotechnologies Corporation



Send2Press® Newswire

Original Image: https://www.send2press.com/wire/images/10-0504-epeiusbio_72dpi.jpg

#

Original Story ID: (6079) :: 2010-07-0706-005

Original Keywords: targeted genetic medicine, Epeius Biotechnologies Corporation, tumor-

targeted gene delivery platform, Regin-G, tumor-seeking nanomedicine, metastatic disease, Orphan Drug status, biologics, broad-spectrum anti-cancer activity, treatment of chemotherapy-resistant cancers Epeius Biotechnologies Corporation San Marino California SAN MARINO, Calif.

Alternate Headline: Epeius Tumor-targeted Gene Delivery Gains in Medicine and Patent Protection

NEWS ARCHIVE NOTE: this archival news content, issued by the news source via Send2Press Newswire, was originally located in the Send2Press® 2004-2015 2.0 news platform and has been permanently converted/moved (and redirected) into our 3.0 platform. Also note the story "reads" counter (bottom of page) does not include any data prior to Oct. 30, 2016. This press release was originally published/issued: Tue, 06 Jul 2010 16:42:17 +0000